AN ENLIGHTENING session, entitled ‘Emerging therapeutic frontiers in cardiology: what does the future hold?’, delivered at ...
While type 1 and type 2 diabetes typically occupy distinct places in healthcare, research is showing an increase of patients ...
The US FDA is advancing the drug approval process for sibeprenlimab, a novel targeted drug to help manage immunoglobulin A nephropathy (IgAN).
Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant ...
Get the latest on Vera Therapeutics, Inc., FDA progress for atacicept, and IgA nephropathy drug competition. Click to what to ...
Zacks Investment Research on MSN
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 ...
HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful ...
The coexistence of type 2 diabetes and obesity represents a major global health challenge that significantly increases cardiovascular and metabolic risk.
Patients with systemic lupus erythematosus and diabetes who received sodium-glucose cotransporter 2 inhibitors exhibited ...
HOUSTON — The benefits of SGLT2 inhibitors in slowing kidney disease progression are similar regardless of patients’ type 2 diabetes (T2D) or albuminuria status, the results of a recent meta-analysis ...
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback